Octaplaslg (Human Plasma Protein)

Octaplaslg is used in clinical situations that require rapid restoration of coagulation factors within the plasma‑derived protein family.

• Massive transfusion protocols: Provides essential clotting factors to control bleeding during massive transfusion.
• Cardiac surgery: Helps maintain hemostasis during cardiopulmonary bypass.
• Liver transplantation: Supplies coagulation proteins needed for patients with impaired liver function.

• Octaplaslg contains a pooled, solvent‑detergent‑treated plasma protein fraction that provides a balanced mixture of clotting factors (including fibrinogen, prothrombin complex, and antithrombin). When infused intravenously, it replaces deficient factors, enabling the coagulation cascade to proceed normally and achieve hemostasis.

Adverse reactions to Octaplaslg are generally infrequent but may occur.

Common Side Effects

• Mild fever: Low‑grade temperature elevation observed in some recipients.
• Headache: Transient headache reported during or after infusion.
• Nausea: Occasional nausea without vomiting.
• Chills: Mild shivering during the infusion.
• Rash: Small erythematous skin lesions at the infusion site.

Serious or Rare Side Effects

• Anaphylactic reaction: Severe allergic response requiring immediate medical intervention.
• Transfusion‑related acute lung injury (TRALI): Acute respiratory distress following infusion.
• Hemolytic transfusion reaction: Destruction of red blood cells due to incompatibility.
• Sepsis: Bacterial contamination leading to systemic infection.
• Thromboembolic events: Formation of clots in vessels causing organ compromise.

When using Octaplaslg, clinicians should observe several safety measures.

• Verify patient identity: Confirm matching blood type and compatibility before infusion.
• Monitor vital signs: Observe blood pressure, heart rate, and oxygen saturation throughout the procedure.
• Assess for allergies: Review patient history for prior reactions to plasma products.
• Use aseptic technique: Maintain sterile conditions to prevent contamination.
• Adjust for volume overload: Consider cardiac status in patients at risk of fluid overload.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octaplaslg may interact with other therapies that affect coagulation or immune response.

Major Interactions (Avoid)

• Warfarin: Concurrent use can excessively prolong clotting times.
• Direct oral anticoagulants (DOACs): May increase bleeding risk when combined.
• High‑dose aspirin or other NSAIDs: Potentiates anticoagulant effect.

Moderate Interactions (Monitor Closely)

• Heparin: Requires careful monitoring of activated partial thromboplastin time.
• Immunoglobulin therapy: May alter immune response and affect plasma protein clearance.
• Corticosteroids: May mask early signs of transfusion reactions.